Conclusion: EUS-FNA has an important role in the diagnosis of mediastinal disease.
Peng HQ, Greenwald BD, Tavora FR, et at Evaluation of performance of EUS-FNA in preoperative lymph node staging of cancers of esophagus, lung, and pancreas.
biopsy is a safe and effective technique for diagnosing and staging PDAC; however, measurement of RNA production can be problematic because of the poor quality of the RNA extracted from these biopsies [(24) and our own experience].
To our knowledge, no one has reported the use of the UFISH test exclusively in pancreatic EUS-FNA specimens, using only UFISH.
We examined our experience with pancreatic specimens obtained by EUS-FNA during a 2-year period.
Material from the EUS-FNA was placed on multiple slides.
During the EUS-FNA procedure, a needle is passed through the esophagus into a MLN.
Fourteen physicians ordered the majority (80%) of cytologic tests before implementation of EUS-FNA, compared with 2 physicians ordering the same fraction after implementation (Pareto chart, Figure 1, A).
Viewed as annual trends, the total number of pancreatic specimens submitted to our laboratory increased gradually from merely 40 specimens in 1990 to 563 in 2010, with a dramatic increase after introduction of the EUS-FNA service (Figure 3).
The reported sensitivities for EUS-FNA
vary widely, from 60% to 100%, with a mean of about 80%, while the specificity again approaches 100%.
As indicated by a recent study and with the current case as an illustrative example, cytopathologists involved in the evaluation of cytologic specimens obtained by EUS-FNA
are likely to encounter a variety of lesions not previously described solely on FNA.
For more information on EUS-FNA
procedures, visit the Boston Scientific Endoscopy Channel at www.